NY-VIACOMCBS-INC.
5.8.2021 13:02:36 CEST | Business Wire | Press release
ViacomCBS Networks International (VCNI), a division of ViacomCBS Inc. (NASDAQ: VIAC, VIACA) and Sky, part of Comcast Corporation (NASDAQ: CMCSA), today announced that Paramount+ will launch on Sky platforms in the UK, Ireland, Italy, Germany, Switzerland and Austria (GSA) in 2022 as part of a new multi-year distribution agreement that also includes the extended carriage of ViacomCBS’ leading portfolio of pay TV channels and the renewal of Sky as an ad sales partner in select markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005410/en/
“We are thrilled to expand our long-standing partnership with Sky to continue delivering ViacomCBS’ leading portfolio of premium entertainment brands to Sky customers and importantly bring Paramount+ to new audiences in all Sky markets, including the UK, Ireland, Italy, and GSA,” said Raffaele Annecchino, President and Chief Executive Officer, ViacomCBS Networks International. “This transformative distribution deal is key to accelerating our global ambitions in streaming while also supporting Sky’s strategic objectives to better serve audiences with greater flexibility in how they consume our content across all platforms.”
Paramount+ is the latest in a series of apps to come to Sky Q adding more than 10,000 hours of content, further enhancing Sky’s aggregation strategy and enabling Sky customers to watch even more of the best content together in one place on the Sky Q platform.
Stephen van Rooyen, Executive VP & Chief Executive, UK & Europe at Sky said: “This is another example of how we are innovating for our customers and further aggregating all the best apps and content together in one place on Sky Q, giving them more great TV to watch than ever before. Paramount+ is an excellent service with a huge range of fantastic films and TV series, and our new, broader agreement with ViacomCBS will benefit both businesses.”
Upon launch, Sky Cinema subscribers will get the bonus of Paramount+ included at no additional cost, providing access to two fantastic services side by side with more than 10,000 hours of extra content for one affordable price. As part of this partnership, Paramount Pictures’ feature films will remain available on Sky Cinema in the UK and will join Sky Cinema in Germany and Italy in 2022. All other Sky customers will be able to subscribe to Paramount+ as an add-on to their account.
Paramount+ features an expansive catalog of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME®, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Outside of the United States, the premium streaming service offers nearly 3,000 episodes of kids’ content, 1,000 episodes of reality, more than 500 films, and 2,500 hours of Paramount+ Originals, CBS and SHOWTIME® series, dramas, and sitcoms.
Titles that will become available through 2022 in the UK, Ireland, Italy and GSA include a collection of scripted, exclusive Paramount+ Originals and exciting new takes on iconic franchises, including HALO , The Offer and the new iCarly series. As the international home of SHOWTIME, the service will offer The Man Who Fell to Earth, Ripley, Super Pumped, and American Gigolo, in addition to popular titles from ViacomCBS, such as Kamp Koral: SpongeBob’s Under Years, Star Trek: Prodigy, and MTV Unplugged. The service will also feature a collection of new movie premieres and fan favorites from Paramount Pictures such as films from the Mission Impossible and Transformer franchises.
In addition, ViacomCBS and Sky reached a multi-year extension for carriage of ViacomCBS’ linear channels — including Comedy Central, MTV and Nickelodeon — in the UK, Ireland, Italy and GSA. The channels will be complemented by a strong selection of box sets, giving customers the flexibility to watch the content they love whenever and wherever they want.
ViacomCBS renewed its multi-year agreement with Sky as an ad sales partner for all platforms and channels in the UK and Italy. Sky Media will continue to handle ad sales across the ViacomCBS portfolio of channels, including Channel 5 in the UK, where ViacomCBS and Channel 5 will benefit from Sky Media’s market-leading innovation in addressable advertising.
Other terms of the agreements were not disclosed.
Paramount+ will also be available direct-to-consumer in UK, Ireland, Italy and GSA through the Paramount+ app for iOS and Android and across supported connected TV devices and OTT platforms. Pricing and local content offering will be announced at a later date.
About Paramount+
Paramount+ is a global digital subscription video streaming service from ViacomCBS that features a mountain of premium entertainment for audiences of all ages. Internationally, the streaming service features an expansive library of original series, hit shows and popular movies across every genre from world-renowned brands and production studios, including SHOWTIME, BET, CBS, Comedy Central, MTV, Nickelodeon, Paramount Pictures and the Smithsonian Channel, in addition to a robust offering of premier local content. Launched on March 4, 2021, the service is currently available in the U.S., Canada, Latin America, and the Nordics, with Australia to launch August 11, 2021. By the end of 2021, ViacomCBS will have launched Paramount+ in 25 markets, ramping to 45 markets by the end of 2022.
For more information about Paramount+, please visit www.paramountplus.com and follow @ParamountPlus on social platforms.
About ViacomCBS Networks International (VCNI)
ViacomCBS Networks International (VCNI), a unit of ViacomCBS Inc. (NASDAQ: VIAC), is comprised of many of the world’s most iconic consumer brands. Its portfolio includes Channel 5, Telefe, Network 10, Nickelodeon, MTV, Comedy Central, BET, Paramount Network, as well as streaming services Paramount+ and PlutoTV, and ViacomCBS International Studios, among others. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution, and advertising solutions for partners on five continents and across more than 180 countries.
VIAC-IR
About Sky
Sky is Europe’s leading media and entertainment company and is part of Comcast Corporation, a global media and technology company. Across six countries, we connect our 23 million customers to the best entertainment, sports, news and arts including our own award-winning original content.
Our technology, including the market leading Sky Q, connects people to everything they love – with entertainment from Sky TV, Netflix, Disney+, Amazon Prime Video and BBC iPlayer, and apps like Spotify, YouTube, BBC Sounds, Highbrow, Peloton, Fiit, and more, in one place, easy. Our streaming service NOW brings viewers all the enjoyment of Sky with the flexibility of a contract-free service. Through our new B2B broadband provider, Sky Connect, we offer superfast broadband with business-grade 4G back-up to small businesses in the UK.
Building on the success of Sky Originals like Chernobyl, Gangs of London and Brassic, we are doubling our investment in original content by 2024 through Sky Studios. Sky News provides impartial and trustworthy journalism for free, Sky Arts is the UK’s only dedicated free-to-air arts channel making the arts accessible for everyone and Sky Sports, our leading sports broadcasting service, brings customers some of the biggest and best global sporting events from the Premier League to Formula 1 and everything in-between. Our new TV and movie studio, Sky Studios Elstree, which will open in 2022, is expected to create over 2,000 new jobs and generate an additional £3 billion of production investment in the UK over the first five years.
We believe that we can be a force for good in the communities in which we operate. We’re committed to being Europe’s first net zero carbon entertainment company by 2030 and we’re proud to be a Principal Partner and Media Partner of COP26. We take pride in our approach to diversity and inclusion: we’ve been recognised by The Times and Stonewall for our commitment to diversity and we’ve set ambitious 2025 targets to continue to increase diversity and representation. We’re also committed to investing £30million across our markets over three years to improve our approach to diversity and inclusion, and to tackle racial injustice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005410/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom